A registry-based cohort study of pulmonary tuberculosis treatment outcomes in Istanbul, Turkey

Aylin Babalik, Zeki Kilicaslan, S. Sevkan Caner, Gokay Gungor, M. Gonenc Ortakoylu, Serap Gencer, Stephen A Mccurdy

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The aim of this study is to evaluate the treatment outcomes and identify factors associated with adverse tuberculosis treatment outcomes for bacteriologically confirmed pulmonary tuberculosis. Treatment outcomes of pulmonary tuberculosis were evaluated retrospectively among 11,186 smearand/ or culture-positive patients treated between 2006 and 2009 in Istanbul, Turkey. Adverse treatment outcomes were identified in 1,010 (9.0z) patients including death (1.8z), treatment default (6.1z), and treatment failure (1.1z). Factors associated with adverse treatment outcomes included being born abroad (odds ratios [OR], 5.38; 95zconfidence intervals [CI], 3.67-7.91), history of tuberculosis treatment (OR, 3.77; 95z CI, 3.26-4.36), age> 65 years (OR, 2.79; 95z CI, 2.21-3.53), and male gender (OR, 1.91; 95z CI, 1.59-2.27). Death was most strongly associated with age > 65 years (OR, 45.1; 95z CI, 27.0-75.6), followed by treatment default with history of interrupted treatment (OR, 11.6; 95z CI, 8.94-15.1), and treatment failure with prior history of treatment failure (OR, 17.1; 95z CI, 6.97-41.6). Multidrug resistance was strongly associated with adverse treatment outcomes (OR, 10.8; 95zCI, 8.02-14.6). Age > 65 years, male sex, being born abroad, and history of treatment failure were found to be risk factors for adverse treatment outcomes. Hence, patients with any of these characteristics should be carefully monitored and treated aggressively.

Original languageEnglish (US)
Pages (from-to)115-120
Number of pages6
JournalJapanese Journal of Infectious Diseases
Volume66
Issue number2
DOIs
StatePublished - 2013

Fingerprint

Turkey
Pulmonary Tuberculosis
Registries
Cohort Studies
Odds Ratio
Treatment Failure
Tuberculosis
Multiple Drug Resistance
Therapeutics

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

A registry-based cohort study of pulmonary tuberculosis treatment outcomes in Istanbul, Turkey. / Babalik, Aylin; Kilicaslan, Zeki; Sevkan Caner, S.; Gungor, Gokay; Gonenc Ortakoylu, M.; Gencer, Serap; Mccurdy, Stephen A.

In: Japanese Journal of Infectious Diseases, Vol. 66, No. 2, 2013, p. 115-120.

Research output: Contribution to journalArticle

Babalik, A, Kilicaslan, Z, Sevkan Caner, S, Gungor, G, Gonenc Ortakoylu, M, Gencer, S & Mccurdy, SA 2013, 'A registry-based cohort study of pulmonary tuberculosis treatment outcomes in Istanbul, Turkey', Japanese Journal of Infectious Diseases, vol. 66, no. 2, pp. 115-120. https://doi.org/10.7883/yoken.66.115
Babalik, Aylin ; Kilicaslan, Zeki ; Sevkan Caner, S. ; Gungor, Gokay ; Gonenc Ortakoylu, M. ; Gencer, Serap ; Mccurdy, Stephen A. / A registry-based cohort study of pulmonary tuberculosis treatment outcomes in Istanbul, Turkey. In: Japanese Journal of Infectious Diseases. 2013 ; Vol. 66, No. 2. pp. 115-120.
@article{ed4b95c877d740649a07eaa58a7bac2c,
title = "A registry-based cohort study of pulmonary tuberculosis treatment outcomes in Istanbul, Turkey",
abstract = "The aim of this study is to evaluate the treatment outcomes and identify factors associated with adverse tuberculosis treatment outcomes for bacteriologically confirmed pulmonary tuberculosis. Treatment outcomes of pulmonary tuberculosis were evaluated retrospectively among 11,186 smearand/ or culture-positive patients treated between 2006 and 2009 in Istanbul, Turkey. Adverse treatment outcomes were identified in 1,010 (9.0z) patients including death (1.8z), treatment default (6.1z), and treatment failure (1.1z). Factors associated with adverse treatment outcomes included being born abroad (odds ratios [OR], 5.38; 95zconfidence intervals [CI], 3.67-7.91), history of tuberculosis treatment (OR, 3.77; 95z CI, 3.26-4.36), age> 65 years (OR, 2.79; 95z CI, 2.21-3.53), and male gender (OR, 1.91; 95z CI, 1.59-2.27). Death was most strongly associated with age > 65 years (OR, 45.1; 95z CI, 27.0-75.6), followed by treatment default with history of interrupted treatment (OR, 11.6; 95z CI, 8.94-15.1), and treatment failure with prior history of treatment failure (OR, 17.1; 95z CI, 6.97-41.6). Multidrug resistance was strongly associated with adverse treatment outcomes (OR, 10.8; 95zCI, 8.02-14.6). Age > 65 years, male sex, being born abroad, and history of treatment failure were found to be risk factors for adverse treatment outcomes. Hence, patients with any of these characteristics should be carefully monitored and treated aggressively.",
author = "Aylin Babalik and Zeki Kilicaslan and {Sevkan Caner}, S. and Gokay Gungor and {Gonenc Ortakoylu}, M. and Serap Gencer and Mccurdy, {Stephen A}",
year = "2013",
doi = "10.7883/yoken.66.115",
language = "English (US)",
volume = "66",
pages = "115--120",
journal = "Japanese Journal of Infectious Diseases",
issn = "1344-6304",
publisher = "National Institute of Health",
number = "2",

}

TY - JOUR

T1 - A registry-based cohort study of pulmonary tuberculosis treatment outcomes in Istanbul, Turkey

AU - Babalik, Aylin

AU - Kilicaslan, Zeki

AU - Sevkan Caner, S.

AU - Gungor, Gokay

AU - Gonenc Ortakoylu, M.

AU - Gencer, Serap

AU - Mccurdy, Stephen A

PY - 2013

Y1 - 2013

N2 - The aim of this study is to evaluate the treatment outcomes and identify factors associated with adverse tuberculosis treatment outcomes for bacteriologically confirmed pulmonary tuberculosis. Treatment outcomes of pulmonary tuberculosis were evaluated retrospectively among 11,186 smearand/ or culture-positive patients treated between 2006 and 2009 in Istanbul, Turkey. Adverse treatment outcomes were identified in 1,010 (9.0z) patients including death (1.8z), treatment default (6.1z), and treatment failure (1.1z). Factors associated with adverse treatment outcomes included being born abroad (odds ratios [OR], 5.38; 95zconfidence intervals [CI], 3.67-7.91), history of tuberculosis treatment (OR, 3.77; 95z CI, 3.26-4.36), age> 65 years (OR, 2.79; 95z CI, 2.21-3.53), and male gender (OR, 1.91; 95z CI, 1.59-2.27). Death was most strongly associated with age > 65 years (OR, 45.1; 95z CI, 27.0-75.6), followed by treatment default with history of interrupted treatment (OR, 11.6; 95z CI, 8.94-15.1), and treatment failure with prior history of treatment failure (OR, 17.1; 95z CI, 6.97-41.6). Multidrug resistance was strongly associated with adverse treatment outcomes (OR, 10.8; 95zCI, 8.02-14.6). Age > 65 years, male sex, being born abroad, and history of treatment failure were found to be risk factors for adverse treatment outcomes. Hence, patients with any of these characteristics should be carefully monitored and treated aggressively.

AB - The aim of this study is to evaluate the treatment outcomes and identify factors associated with adverse tuberculosis treatment outcomes for bacteriologically confirmed pulmonary tuberculosis. Treatment outcomes of pulmonary tuberculosis were evaluated retrospectively among 11,186 smearand/ or culture-positive patients treated between 2006 and 2009 in Istanbul, Turkey. Adverse treatment outcomes were identified in 1,010 (9.0z) patients including death (1.8z), treatment default (6.1z), and treatment failure (1.1z). Factors associated with adverse treatment outcomes included being born abroad (odds ratios [OR], 5.38; 95zconfidence intervals [CI], 3.67-7.91), history of tuberculosis treatment (OR, 3.77; 95z CI, 3.26-4.36), age> 65 years (OR, 2.79; 95z CI, 2.21-3.53), and male gender (OR, 1.91; 95z CI, 1.59-2.27). Death was most strongly associated with age > 65 years (OR, 45.1; 95z CI, 27.0-75.6), followed by treatment default with history of interrupted treatment (OR, 11.6; 95z CI, 8.94-15.1), and treatment failure with prior history of treatment failure (OR, 17.1; 95z CI, 6.97-41.6). Multidrug resistance was strongly associated with adverse treatment outcomes (OR, 10.8; 95zCI, 8.02-14.6). Age > 65 years, male sex, being born abroad, and history of treatment failure were found to be risk factors for adverse treatment outcomes. Hence, patients with any of these characteristics should be carefully monitored and treated aggressively.

UR - http://www.scopus.com/inward/record.url?scp=84875315581&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875315581&partnerID=8YFLogxK

U2 - 10.7883/yoken.66.115

DO - 10.7883/yoken.66.115

M3 - Article

C2 - 23514907

AN - SCOPUS:84875315581

VL - 66

SP - 115

EP - 120

JO - Japanese Journal of Infectious Diseases

JF - Japanese Journal of Infectious Diseases

SN - 1344-6304

IS - 2

ER -